BioTuesdays

Category - Markets

AzurRx BioPharma
Markets

Roth starts AzurRx BioPharma at buy; PT $10.50

Roth Capital Partners launched coverage of AzurRx BioPharma (NASDAQ:AZRX) with a “buy” rating and price target of $10.50. The stock closed at $2.25 on Jan. 25. AzurRx is developing non-systemic, recombinant enzyme...

January 28, 2019
Bellerophon Therapeutics
Markets

Maxim starts Bellerophon Therapeutics at buy; PT $3

Maxim Group initiated coverage of Bellerophon Therapeutics (NASDAQ:BLPH) with a “buy” rating and $3 price target. The stock closed at 67 cents on Jan. 23. Bellerophon’s lead product is the INOpulse delivery system of...

January 24, 2019
CannTrust Holdings
Markets

Paradigm starts CannTrust Holdings at buy; PT $18

Paradigm Capital launched coverage of CannTrust Holdings (TSX:TRST) with a “buy” rating and $18 price target. The stock closed at $8.35 on Jan.18. “CannTrust brings to the cannabis space a practice of professionalism...

January 18, 2019
Markets

HCW ups Aeterna Zentaris PT to $5.50 from $3

H.C. Wainwright raised its price target for Aeterna Zentaris (NASDAQ, TSX:AEZS) to $5.50 from $3 after its Macrilen agent for adult growth hormone deficiency (AGHD) was approved for sale in the EU. The stock closed at...

January 17, 2019
Puma Biotechnology Logo
Markets

Leerink starts Puma Biotech at MP; PT $21

Leerink launched coverage of Puma Biotechnology (NASDAQ:PBYI) with a “market perform” rating and $21 price target. The stock closed at $25.33 on Jan. 16. Puma is a single-product commercial-stage biotech company...

January 17, 2019
Dyadic
Markets

Noble starts Dyadic at OP; PT $4

Noble Capital Markets initiated coverage of Dyadic International (OTC:DYAI) with an “outperform” rating and price target of $4. The stock closed at $1.96 on Jan. 9. Over the past two decades, Dyadic has developed an...

January 10, 2019
Canopy Growth Logo
Markets

Piper Jaffray starts Canopy Growth at OW; PT $40

Piper Jaffray launched coverage of Canopy Growth (NYSE:CGC; TSX:WEED) with an “overweight” rating and $40 price target. The stock was quoted at $32.16, up $2.52, around midday on Jan 9. “While it is difficult to...

January 9, 2019
Millendo Therapeutics
Markets

Ladenburg starts Millendo Therapeutics at buy; PT $29

Ladenburg Thalmann launched coverage of Millendo Therapeutics (NASDAQ:MLND) with a “buy” rating and $29 price target. The stock closed at $7.65 on Jan. 3. Millendo is a clinical-stage company focusing on the development...

January 4, 2019